Phase 3 is where the peptide pipeline actually monetizes. The trials that drive prescribing labels and payer coverage land here.
Recent and active Phase 3 programs covered on this site: SURMOUNT-5 (tirzepatide vs semaglutide), ACHIEVE-3 (orforglipron in obesity), TRIUMPH (retatrutide), REDEFINE-1 and -2 (CagriSema), SYNCHRONIZE-1 (Zealand's survodutide), REMODEL (semaglutide kidney), the SELECT cardiovascular outcomes trial, BriaCell's Bria-IMT in metastatic breast cancer, and AMPLIFY-201 (ELI-002 KRAS vaccine). Outside obesity and oncology, Boehringer Ingelheim, Crinetics, Verismo, and Lirum have active Phase 3 readouts in adjacent indications.
Stories here cover top-line readouts, full-data presentations at AACR, AAN, ESCMID, and AOSSM, and the FDA filings that follow.
Boehringer Ingelheim confirmed completion of the 76-week primary endpoint visit for the last participant in Phase 3 SYNCHRONIZE-1. Topline data expected H1 2026 — making it one of the year's most anticipated obesity readouts. Survodutide is a glucagon/GLP-1 dual agonist co-developed with Zealand Pharma. The comprehensive SYNCHRONIZE program also includes SYNCHRONIZE-CVOT (cardiovascular outcomes, fully enrolled). All key trials are scheduled to read out at scientific meetings throughout 2026, potentially paving the way for regulatory submission as the third major obesity GLP-1-class drug after semaglutide and tirzepatide.
Novo Nordisk announced April 23 positive topline results from the PIONEER TEENS trial: a 52-week, randomized, double-blind, placebo-controlled Phase 3a study of oral semaglutide (3, 7, or 14 mg once daily) in 132 children and adolescents aged 10-17 with type 2 diabetes. Oral semaglutide reduced HbA1c by 0.83 percentage points more than placebo at 26 weeks with a well-tolerated safety profile. Pending regulatory approvals, it would be the first oral GLP-1 RA for this pediatric population. Novo expects to file for label expansion in the US and EU in H2 2026.
Ahead of Amgen's April 30 Q1 2026 earnings release, analyst coverage highlighted MariTide as the company's most closely-watched pipeline asset. The bispecific GLP-1 RA / GIPR antagonist delivered up to 20% weight loss at 52 weeks in Phase 2 and is now enrolled across six global Phase 3 trials — with monthly, bi-monthly, and potentially quarterly dosing as its primary commercial differentiator against weekly GLP-1s. Amgen recorded $35.1 billion in 2025 product sales (+10%), and MariTide headline data from the Phase 3 program is expected to begin reading out in 2027.
CLINUVEL presented afamelanotide (Scenesse) vitiligo data at the American Academy of Dermatology annual meeting to 20,000+ delegates. The Phase III CUV105 trial has completed enrollment of 200+ patients across 3 continents. Clinical cases showed repigmentation after 20 weeks maintained through 6-month follow-up, even in patients with active disease. Topline results expected H2 2026.
Eli Lilly's triple-agonist retatrutide met all primary and key secondary endpoints in Phase III TRIUMPH-4. The 9mg and 12mg doses achieved significant weight loss and knee pain reduction at 68 weeks in patients with obesity and osteoarthritis. Seven more Phase III readouts expected in 2026.
Retatrutide met its primary endpoint of superior A1C reduction and all key secondary endpoints at 40 weeks compared with placebo in type 2 diabetes patients, also demonstrating significant weight loss.
Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.